awmsg logo



lurasidone (Latuda®)


Reference No. 1142

Publication date:
11/03/2015


Appraisal information

lurasidone (Latuda®) 18.5 mg film-coated tablet
lurasidone (Latuda®) 37 mg film-coated tablet
lurasidone (Latuda®) 74 mg film-coated tablet


Company: Sunovion Pharmaceuticals Europe Ltd
BNF category: Central nervous system
NMG meeting date: 07/01/2015
AWMSG meeting date: 11/02/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0115
Ministerial ratification: 10/03/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Lurasidone (Latuda®) is recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults aged 18 years and over.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download